Rhythm specializes in treatments for metabolic conditions and severe obesity.
By Sabrina Valle, Milana Vinn and Amy-Jo Crowley Nov 4 (Reuters) - AstraZeneca made an offer of about $10 billion to acquire ...
AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...
Strategic partnerships and accelerating trial readouts position the company to replace revenue lost to patent cliffs.
AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not ...
AstraZeneca PLC (LSE:AZN, NYSE:AZN), the Anglo-Swedish drugmaker, saw three brokers raise their price targets after its third ...
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
By Pushkala Aripaka and Patrick Wingrove Oct 30 (Reuters) - AstraZeneca on Friday unveiled a restructuring programme aimed at ...
Executive Vice President, BioPharmaceuticals Business Unit - Ruud Dobber ...
Rhythm (RYTM) stock jumped 28% to $110.68 after reports AstraZeneca offered up to $134 a share, about $10 billion, to buy the ...
AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the pharmaceutical industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results